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Risks Associated with Strict Glycemic Control of the Type 2 Diabetic Patient in the Intensive
Care Unit
Abstract
Type 2 diabetes mellitus (T2DM) is a very prevalent chronic disease in the United States
that costs Americans billions of dollars each year. According to the Center for Disease Control,
more than 30 million people in the world are affected by diabetes and roughly 95% of those
people have T2DM (2018). The prevalence of diabetes is even more predominant in the critical
care setting, when compared to the general population. The case description in this report
highlights a 65-year-old woman with T2DM and the management of the disease in the outpatient
setting. Due to the progression of this disease, T2DM is frequently having to be managed on the
inpatient setting in the critically ill with the use of insulin. There has been considerable debate
over the last two decades as to the proper protocols when managing glycemic control in the
critical care setting with the use of insulin. This literature review will focus on the current
guidelines of glycemic control for T2DM in the intensive care unit (ICU) and why they are
focused on a more lenient approach versus a stricter approach. The review will also look into
hypoglycemia and glycemic variability as risks associated with strict glycemic control in the
ICU. The clinical relevance of this topic is that up to 40% of the patients that are admitted to ICU
are affected by type 2 diabetes, so the need for knowledge on appropriate guidelines and risks of
strict control should be well understood (Palesh, Jones, Horowitz, & Deane, 2015).
Background
Type 2 diabetes can be managed in a variety of different ways. Often on the outpatient
setting, patients are able to control their diabetes with oral and injectable medications until
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insulin may be warranted. More frequently in the inpatient setting, the use of insulin is the sole
use for management of glycemic control. Outlined below is a case report of a type 2 diabetic
patient in which a combination of injectable and oral medications is used to control her diabetes.
The case report highlights the fact that management is often complicated and must be
personalized to the patient. Glycemic control can be achieved in numerous different ways but
patient compliance, as well as life style modifications, can be used to help to predict success.
The purpose of this report is to investigate conventional versus strict glycemic control of
the type 2 diabetic patient in the ICU and the associated risks of hypoglycemia and glycemic
variability when a strict approach is used. The rationale behind this topic is the fact that there has
been much debate over the last 15 years in regard to the guidelines for optimal glycemic control
in the ICU, with lesser focus being on the diabetic patient. Diabetes is a very common disease in
this country as currently about 13% of the population of the United States is affected by diabetes,
in which 40% of it is undiagnosed (Palesh et al., 2015). When looking at prevalence of diabetes
specifically in the ICU, it is estimated that up to 40% of patients admitted have diabetes, with
undiagnosed diabetes being about 6-14% (Palesh et al., 2015). This literature review will look
into the current guidelines for glycemic control of the type 2 diabetic patient in the critical care
setting and why they are focused on a more conventional approach versus a stricter approach.
This review will also highlight the associated risks of strict glycemic control including
hypoglycemia and glycemic variability and their associated implications for patients.
Case Report
A 65-year-old Caucasian female presents to a primary care clinic for a 6-month diabetes
follow up. Patient has a history of T2DM in which she reports was diagnosed 10 years ago.
Patient reports no concerns in regard to today’s visit and states she is compliant with her
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medications. She reports she currently takes Glipizide 10mg daily and Janumet 50-1000mg
twice daily for her diabetic regimen. She reports checking her blood sugar 2-3 times a week and
fasting values have ranged from 170-220s. When asked, she denies carbohydrate counting or
regular exercise. She reports about a 5-10 pound weight gain this winter. Denies polydipsia,
polyphagia, or polyuria. Denies any low blood sugars. She denies any open sores or non-healing
wounds. Patient states that she does see the eye doctor on a yearly basis. Patient denies vision
changes, headaches, chest pain, shortness of breath, abdominal pain, blood in stool/urine,
fever/chills, body aches, or generalized malaise.
Patient’s pertinent medication history includes hypertension, obesity and hyperlipidemia.
Her current prescription medication list includes Lisinopril 10mg daily, Toprol XL 50mg daily,
Zocor 20mg daily, Aspirin 81mg daily, and a multivitamin. She has no allergies. Her pertinent
surgical history is negative. Patient states only pertinent family history includes her father with
noted “heart problems.” Patient currently lives with her husband in town and is a retired teacher.
She has two grown children and no grandchildren. She denies tobacco use and reports occasional
alcohol use on the weekends. She is up to date with her immunizations except her pneumococcal
vaccine.
Patient’s vital signs during the visit are as follows: blood pressure - 138/80, heart rate –
72, respiration rate – 18, weight - 122kg, and BMI – 36.5 kg/m2. Upon physical exam, she is
alert and orientated and in no acute distress. Red reflex is present in both eyes bilaterally and
fundi are clear and with no arteriovenous nicking or retinopathy. Mucous membranes are pink,
moist and intact. Upon auscultation, heart rate and rhythm are regular. No murmurs are heard.
Lungs are clear to auscultation to bilateral lung fields. No enlarged lymph nodes are palpated.
Her extremities are warm and well perfused. Her radial, pedal, and dorsalis pedis pulses are
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palpable at a +2 grade. Her skin has no open areas and no obvious deformities are noted.
Diabetic foot exam was performed, and full sensation was noted with 10-gram monofilament and
vibratory tool. No open areas or calluses noted. Feet appear well moisturized and toenails are
intact and not thickened. There is no swelling, tenderness, or erythema noted.
Fasting labs were ordered including a microalbumin urine, lipid profile, comprehensive
metabolic panel, and hemoglobin A1C. Lab values were as follows: fasting glucose 324 mg/dL,
Hgb A1C 9.5%, triglycerides 167 mg/dL, HDL 39 mg/dL, and LDL 61 mg/dL. Her A1C six
months ago was 8.1%. Her microalbumin and creatinine urine were within normal limits (WNL).
All others laboratory values were WNL.
Diagnosis for today’s visit included Type 2 Diabetes Mellitus without complications,
uncontrolled. Results were discussed with patient. Plan going forward includes discontinuing
Janumet and Glipizide. Liraglutide (Victoza) subcutaneous injection ordered at a dose of 0.6mg
daily for 1 week; then instructed to increase to 1.2 mg daily thereafter. Metformin 1000mg twice
daily ordered as well. Patient educated on common gastro-intestinal side effects and black box
warning of Victoza on thyroid tumors. Patient encouraged to check blood sugars two times daily,
fasting and post-prandial, until next visit. Patient also to be scheduled to see diabetic educator.
Patient encouraged to engage in thirty minutes of aerobic exercise five times a week. A nurse
from the clinic will plan to reach out to patient in the next 1-2 weeks to review blood sugars and
assess how the new medication regimen is going. The plan is to follow up in three months for a
diabetic follow up with fasting labs. Pneumococcal vaccine (PSV-13) will be administered today
in clinic.
Literature Review
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Glycemic control of the critically ill patient with T2DM has been a topic of attention for
the last 15 years. There is debate whether strict glucose control serves better for this population
versus conventional glycemic control. T2DM continues to remain very prevalent in our society
in the United States. The case report described above shows the numerous ways that T2DM can
be managed in an outpatient setting. T2DM is managed very differently in the inpatient setting.
As stated above, compared to the general population, T2DM is more prevalent in hospitalized
patients. The prevalence of T2DM in the intensive care unit (ICU) is estimated to be anywhere
from 12-40% (Palesh et al., 2015). Hospital prevalence of undiagnosed T2DM is about 6-14%
of patients. This is an important finding to keep in mind due to the fact that chronic glucose
control may have implications on the optimal glycemic control during their stay in the ICU
(Palash et al., 2015). It is recommended that a Hgb A1C be checked upon admission to the ICU
if no prior records of one available within the last three months (ADA, 2016).
Glycemic Control
A literature review conducted on optimal glucose control for the critically ill type 2
diabetic patient found that the risks of strict glycemic control in the ICU outweighs the benefits.
A landmark study titled The NICE-SUGAR Study (2009) found that that intensive glucose control
versus conventional glucose control increased the absolute risk of death in the patients by 2.6%.
Intensive glucose control was defined as target ranges of 80-110 mg/dL for blood sugars and
conventional was defined as 140-180 mg/dL. This study still remains the most comprehensive
study of glycemic control strategies performed to date in the critical care setting. There was also
shown to be a significant increase in severe hypoglycemia in the group being treated with strict
glucose control. Severe hypoglycemia was found to occur in 6.8% of patients who were part of
the intensive insulin therapy, versus 0.5% in the conventional insulin therapy group. In the
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subgroup analysis there was no statistical difference in treatment effects when comparing
patients with or without type 2 diabetes (Van den Berghe). This study, along with Clain, Ramar,
& Surani (2015), Luethi et al., (2018), Palesh et al., (2015), and the American Diabetes
Association (2016), recommend a starting threshold for treatment of insulin therapy at >180
mg/dL. Once insulin therapy is initiated, target goal of blood sugars should range from 140-180
mg/dL (versus 80-110 mg/dL). The American Diabetes Association (2016) does point out that
more stringent goals of glucose control, such as 110-140 mg/dL, may be appropriate in some
critically ill patients if able to avoid significant hypoglycemia. These studies had a common
theme of increased mortality of patients being treated with strict glycemic parameters during
their stay in the ICU. Not only did the literature support increased mortality with strict glycemic
control, but also showed an increase in hypoglycemia and glycemic variability, which can also
have adverse effects on patients. Although uncontrolled hyperglycemia is clearly harmful to
patients with T2DM in the ICU, there has been inconsistent data as to its effects on mortality and
morbidity on patients (Palesh, et al., 2015). Any state of health where the body is stressed,
including a period of disease, some degree of hyperglycemia is to be expected and can be seen as
protective. Severe hyperglycemia is thought to be a marker of illness severity and often subsides
after the illness has resolved (Silva-Perez, Benitez-Lopez, Varon & Surani, 2017).
As outlined above, it is clear that the current literature does not support strict glycemic
control of the critically ill with T2DM. Evidence supports that the risks outweigh the benefits in
this population. Hypoglycemia and glycemic variability are two major risks that have been
shown to occur with strict glycemic control and are discussed below.
Hypoglycemia
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Numerous articles reviewed on the topic of hypoglycemia in the critically ill with T2DM
demonstrated the harmful effects it can have on this population. Hulkower, Pollack, & Zonszein,
(2014), Braithwaite et al., (2017), Claine et al., (2015), Silva-Perez et al., (2017), and MartinTimon & Canizo-Gomez (2015) report that hypoglycemia is associated with increased morbidity
and mortality in the type 2 diabetic patient in the ICU. Hypoglycemia can be defined as a blood
sugar <70 mg/dL. It is more common in those with T1DM, but due to the overwhelming
presence of T2DM in the inpatient setting, it is seen more frequently in the patient with T2DM in
the hospital setting (Hulkower et al., 2014). The literature also supports that there are numerous
harmful effects that hypoglycemia can have in the critically ill diabetic patient. For example,
Hulkower et al., (2014) and Silva-Perez (2017) agree that hypoglycemia can affect cognitive
function in adults and cause brain injuries. Hypoglycemia can lead to neuronal death that may
damage areas of the brain that oversea memory. Behavioral changes, cognitive impairment, and
seizures are all neurological complications that can occur due to hypoglycemia in the diabetic
patient.
Hulkower et al., (2014), along with Silva-Perez (2017), Martin-Timon (2015), and Suh &
Kim (2015) particularly point out the cardiovascular implications that can occur when
hypoglycemia is present. Hypoglycemia triggers the sympathetic nervous system causing
adrenaline secretion. This may induce arrhythmias, as well as increase cardiac workload, which
may be fatal to diabetic patients, especially those with underlying endothelial dysfunction. In
patients with T2DM and coronary artery disease, hypoglycemia was shown to be associated with
electrocardiogram changes along with chest pain, that could account for sudden mortality. ECG
changes include increased QT intervals and changes in cell repolarization, which can lead to life
threatening ventricular arrhythmias. Patients who experienced severe hypoglycemia showed to
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have an increased likelihood of experiencing acute cardiovascular events when compared to
patients without severe hypoglycemia. Palesh et al., (2015) specifically points out that
hypoglycemia can increase the inflammatory response, impair sympathetic nervous system,
inhibit the stress response, induce cerebral vasodilation, and increase neural defects. Due to the
rising increase of diabetic patients in the critical care setting, the risk of severe hyperglycemia is
quite high. The consequence though of treating severe hyperglycemia is hypoglycemia. This
puts diabetic patients even more at risk for hypoglycemia, as patients with persistent states of
hyperglycemia due to insulin resistance are more likely to require control with insulin (SilvaPerez et al., 2017). Proper use of current evidence based literature on glycemic control protocols
for this population is critical to avoid the harmful effects that can occur from hypoglycemia.
Glycemic Variability
Glycemic variability is another risk that can occur with strict glycemic control in the ICU
and can be potentially harmful to diabetic patients. Glycemic variability is the fluctuation in
blood glucose concentrations and there is currently no established gold standard guideline for
measuring this (Palesh et al, 2015) & (Caine et al. 2015). When patients are treated with stricter
insulin parameters, the likelihood of variable highs and lows in blood glucose ranges is
increased. Palesh et al. (2015), Baptista et al., (2018), Suh & Kim (2015), and Caine et al.,
(2015) all had the common theme that glycemic variability in the critically ill type 2 diabetic is
likely to increase mortality and cause other complications. This was found to be an independent
predictor of mortality. The use of strict glycemic control protocols in the ICU was shown to
increase glycemic variability, thus potentially causing adverse effects to those patients affected.
Patients with T2DM are more at risk for glycemic variability due to increased chance of needing
insulin treatment for blood glucose management.
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The literature review on this topic supports that glycemic variability has been shown to
increase cell death, increase cytokine production, impair endothelial function, and increase
oxidative stress (Palesh et al., 2015), (Baptista et al., 2018), (Suh & Kim, 2015), and (Caine et
al., 2015). This can lead to further vascular complications, both microvascular and
macrovascular effects. Suh & Kim reported that even short-term glucose variability can play a
substantial role in the development of microvascular complications, specifically retinopathy
(2015). When blood sugar drops from a high value to a low value, an inflammatory response is
initiated which induces the release of inflammatory cytokines. This also leads to an increase in
both platelet and neutrophil activation. This can cause adverse effects to the type 2 diabetic
patient as it often increases cardiovascular risk due to endothelial dysfunction (Suh & Kim,
2015). Baptista et al. (2018) pointed out that glycemic variability not only lead to an increase
risk of mortality, but also was shown to increase length of hospital stay and mechanical
ventilation days. One important takeaway from this particular study was the importance of
sufficient nursing participation in controlling glucose levels in order to increase survival rates
and ensure effective care. Palesh et al., does point out that data is somewhat inconsistent as to
whether or not patients with diabetes who experience glucose variability are in fact at an
increased risk for mortality. The article mentions this may be due to the fact that only a small
number of studies have been conducted on this topic specifically related to patients with diabetes
and that chronic hyperglycemia can be seen as somewhat protective in acute illness. Further
research on this topic for this specific population is recommended (2015).
In conclusion, glycemic control of patients with T2DM in the critical care setting is not
always an easy thing to achieve. Currently, guidelines recommend approaching these patients
with a more lenient approach, versus a stricter approach. Insulin therapy is recommended to start
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when blood sugars reach 180 mg/dL, with a target range of 140-180 mg/dL. Hypoglycemia and
glycemic variability are two main adverse effects that are more likely to occur when a stricter
protocol is in place for glycemic control. These have both been shown to have many associated
undesirable effects, as well as increasing mortality in this patient population.
Literature Search
A thorough literature search was conducted to yield adequate articles appropriate for this
research topic. A literature search of the key words “type 2 diabetes” in the major database of
CINAHL (Cumulative Index to Nursing & Allied Health) revealed over 20,000 articles.
CINAHL is a very widely used and respected database that covers numerous areas in the
profession of nursing. To narrow the search, search terms “type 2 diabetes” along with subject
major heading “critical care” was used. Limiters placed included English language, published in
the years 2014-2019, and peer reviewed articles. This search narrowed down the number of
appropriate articles greatly and one article was selected. A search of the key works
“hypoglycemia” and “ICU” yielded 22 articles in which two were chosen. An additional search
on CINAHL with key works “glucose control” and “critical care” yielded one article that was
chosen.
Another search was conducted in the major database of PubMed. This database focuses
on more biomedical and clinical literature. A search of “World Journal of Diabetes” with the
same limiters as listed above, yielded three appropriate articles. The World Journal of Diabetes
articles were used throughout an UpToDate review of this topic, in which PubMed was used to
find the primary source. An additional search of “glycemic variability” was used in PubMed in
which two articles where chosen. PubMed was also used to find the landmark study from the
New England Journal of Medicine on the NICE-SUGAR study. The American Diabetes
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Association provided statistics along with current guideline recommendations and was a helpful
tool in this literature search.
Learning Points
•

Currently, guidelines of glycemic control in the intensive care unit are focused on a
conventional approach versus a strict approach, as risks have been shown to outweigh the
benefits. Guidelines state that insulin therapy should be initiated when blood sugar has
reached 180 mg/dL, with a target range of 140-180 mg/dL while receiving insulin
therapy.

•

The risk of hypoglycemia that can occur with strict glycemic control in the type 2
diabetic patient has been shown to increase mortality in the ICU. Hypoglycemia has also
been shown to have detrimental cardiovascular and neurological implications in critically
ill patients with T2DM.

•

The risk of glycemic variability has also been shown to increase mortality in the type 2
diabetic patient in the ICU. This can contribute to microvascular and macrovascular
complications and is a greater risk when strict glycemic parameters are in place. More
research is recommended for diabetics specifically and the implications of glycemic
variability.
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